

Proposal serology EQA SARS-CoV-2

Panel composition – pos. samples	<ul style="list-style-type: none"> <li>• Serum only (no saliva)</li> <li>• 2-3 samples with medium / high titers from severely ill cases</li> <li>• 2-3 samples with medium / high titers from mild cases</li> <li>• All pos. samples should be confirmed PCR-positive and from otherwise healthy individuals (i.e. not immunocompromised)</li> <li>• All pos. samples should be tested in as many tests as possible by INMI and RIVM: IF, Wantai, ELISA (?), automated system (?), VNT, other tests (?) -&gt; IgG, IgM and IgA -&gt; samples will always contain all subtypes or at least IgG and IgM (?)</li> </ul>
Panel composition – neg. samples	<ul style="list-style-type: none"> <li>• 2 x negative control samples -&gt; serum collected before 2019</li> <li>• If available serum with high beta-coronavirus titer -&gt; RIVM has to check if possible</li> <li>• EBV infection serum</li> <li>• CMV infection serum</li> </ul>
Panel properties	<ul style="list-style-type: none"> <li>• 12 ml needed / sample</li> <li>• 9-11 samples / panel</li> <li>• 2 options for composition: <ul style="list-style-type: none"> <li>○ 50 panels à 200 ul / sample</li> <li>○ 66 panels à 150 ul / sample</li> </ul> </li> <li>• All sera have to be tested in PCR for Hepatitis A, B, C, E (?), HIV, SARS-CoV-2</li> <li>• transport and storage conditions depend on lyophilization</li> </ul>
Budget	<ul style="list-style-type: none"> <li>• (10)(2b) for panel production and shipment</li> <li>• (10)(2b) for administrative costs</li> </ul>
Open questions	<ul style="list-style-type: none"> <li>• Can samples be lyophilized in time?</li> <li>• Which laboratories can participate – ECDC selection based on country (?)</li> <li>• How to proceed with heat inactivation?</li> </ul>